CCM
ALNY icon

Cinctive Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cinctive Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,300
Closed -$2.02M – 377
2024
Q2 		$2.02M Buy
+8,300
New +$1.31M 0.1% 254

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Cinctive Capital Management's ALNY Position: Q3 2025 in Review

Cinctive Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 22,868 shares — an estimated $7.46M sold.

Cinctive Capital Management first reported a position in ALNY in Q4 2020 and held it in 7 quarters. The position peaked at $7.46M in Q2 2025. 822 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Cinctive Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 22,868 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $7.46M.
  • Cinctive Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • Cinctive Capital Management's Alnylam Pharmaceuticals position peaked at $7.46M in Q2 2025.
  • 822 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.